On Feb. 10, 2023, the U.S. Food and Drug Administration issued an emergency use authorization for the first mpox test for use in a point-of-care setting.

Validation data to support the EUA for the Cepheid Xpert Mpox test was gathered through the National Institutes of Health Independent Test Assessment Program established as a collaboration between the FDA and the NIH.